280
Participants
Start Date
July 11, 2023
Primary Completion Date
June 15, 2027
Study Completion Date
June 15, 2027
AZD5863
T cell-engaging bi-specific antibody that targets CLDN18.2 (Claudin18.2) on tumor cells and CD3 on T cells
WITHDRAWN
Research Site, New York
RECRUITING
Research Site, Toulouse
RECRUITING
Research Site, Jacksonville
RECRUITING
Research Site, Rochester
RECRUITING
Research Site, Tainan City
RECRUITING
Research Site, Kaohsiung City
RECRUITING
Research Site, Villejuif
RECRUITING
Research Site, Beijing
RECRUITING
Research Site, Beijing
RECRUITING
Research Site, Shandong
RECRUITING
Research Site, Chūōku
RECRUITING
Research Site, Kashiwa
RECRUITING
Research Site, Kōtoku
RECRUITING
Research Site, Amsterdam
RECRUITING
Research Site, Groningen
RECRUITING
Research Site, Rotterdam
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Seoul
RECRUITING
Research Site, Taoyuan District
RECRUITING
Research Site, Dundee
RECRUITING
Research Site, London
RECRUITING
Research Site, Metropolitan Borough of Wirral
RECRUITING
Research Site, Oxford
Lead Sponsor
AstraZeneca
INDUSTRY